
Tesamorelin and CJC-1295 work on the same receptor. Both are synthetic versions of growth hormone-releasing hormone (GHRH), which tells the pituitary gland to release growth hormone. They differ in structure, how long they last, and how much human evidence backs them.
The short answer: tesamorelin is FDA-approved and has the strongest clinical evidence for one thing: reducing visceral belly fat. CJC-1295 is not FDA-approved, but is widely used, usually paired with ipamorelin, for broader goals like recovery, sleep, and lean muscle.
Both mimic GHRH, the hormone your hypothalamus releases to signal the pituitary. When they bind the GHRH receptor:
Because they work through your own pituitary, both keep your body's natural feedback loops in place. That's a key difference from injecting growth hormone directly.
Structure. Tesamorelin is the full-length GHRH molecule with a small modification that protects it from breaking down. CJC-1295 is a shortened version, the 29 amino acids that do the signaling, with four substitutions that make it more stable.
Duration. CJC-1295 comes in two forms:
Tesamorelin falls in between, with a short half-life and a once-daily injection.
Evidence. Tesamorelin went through large phase 3 trials and FDA approval. CJC-1295 has a small number of early human studies.
Tesamorelin has the stronger evidence. In a 26-week phase 3 trial of 412 people with HIV and abdominal fat buildup, tesamorelin reduced visceral fat by 15.2%, while it increased by 5.0% on placebo. It also improved triglycerides and cholesterol, with little effect on fat under the skin. This research led to its FDA approval as Egrifta.
CJC-1295 raises GH and IGF-1, which should promote fat loss, but it has not been tested in a dedicated fat-loss trial. If visceral fat is your main concern, tesamorelin is the evidence-based choice. Learn more in our guide to tesamorelin benefits.
In healthy adults, a single dose of CJC-1295 with DAC raised growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for up to 11 days. That sustained rise is what made it popular for recovery and lean mass goals.
Today, most protocols use CJC-1295 without DAC alongside ipamorelin, a ghrelin-receptor peptide. CJC-1295 amplifies the size of each GH pulse, while ipamorelin triggers the pulse. Together they produce a stronger, more natural GH release than either alone. See our guide to CJC-1295 and ipamorelin.
Both are generally well tolerated. Shared side effects include:
Because both raise IGF-1, they can modestly raise blood sugar in some people, so clinicians may check glucose and IGF-1 during treatment. Neither should be used by people with active cancer or during pregnancy.
CJC-1295 with DAC can cause more persistent side effects because of its long action, which is one reason the no-DAC version is preferred.
No. CJC-1295 reached early clinical trials in the mid-2000s, but development stopped and it was never approved. It's available through some compounding pharmacies with a prescription.
Tesamorelin is FDA-approved as Egrifta for reducing excess abdominal fat in people with HIV-associated lipodystrophy. Its use for visceral fat in other adults is off-label.
Be cautious with "research" versions of either peptide sold online. These are not made by licensed pharmacies and are labeled "not for human use." Learn why sourcing matters in our guide to research-grade peptides vs licensed pharmacies.
Tesamorelin may be better if you:
CJC-1295 (with ipamorelin) may be better if you:
Usually not. Both act on the same GHRH receptor, so combining them adds little. Tesamorelin is more often paired with ipamorelin.
For visceral fat, tesamorelin has much stronger evidence. For raising GH overall, both are effective; CJC-1295 with DAC produces the longest-lasting rise.
It's CJC-1295 without the drug affinity complex that extends its half-life. It acts for about 30 minutes and produces a natural GH pulse. It's also called modified GRF 1-29.
Changes in visceral fat were measured at 26 weeks in clinical trials, though some people notice changes in waist size sooner.
Yes. Egrifta is the brand name for tesamorelin.
Tesamorelin and CJC-1295 both mimic GHRH, but tesamorelin is the proven visceral fat reducer. Tesamorelin has FDA approval and phase 3 data showing about 15% visceral fat reduction. CJC-1295, usually combined with ipamorelin, is a popular choice for overall GH support, recovery, and body composition.
Bowery Clinic offers both Tesamorelin and CJC-1295 + Ipamorelin after a quick online evaluation. Compare more growth hormone peptides in our guides to tesamorelin vs sermorelin, tesamorelin vs ipamorelin, and HGH peptides. See what our patients say.

